hereditary hemorrhagic telangiectasia
Information
- Disease name
- hereditary hemorrhagic telangiectasia
- Disease ID
- DOID:1270
- Description
- "A vascular disease characterized by the presence of multiple arteriovenous malformations that lack intervening capillaries and result in direct connections between arteries and veins." [url:http\://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia, url:http\://ghr.nlm.nih.gov/condition/hereditary-hemorrhagic-telangiectasia, url:http\://www.ncbi.nlm.nih.gov/books/NBK1351/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04874558 | Active, not recruiting | Ultra-low-dose Chest CT for HHT | May 1, 2021 | May 1, 2024 | |
| NCT04646356 | Active, not recruiting | Phase 2 | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | October 20, 2020 | December 2024 |
| NCT05550376 | Active, not recruiting | Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia | April 30, 2021 | June 30, 2024 | |
| NCT04150822 | Active, not recruiting | Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry | November 1, 2018 | December 2028 | |
| NCT00389935 | Completed | Phase 2 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | October 2006 | July 2011 |
| NCT01031992 | Completed | Phase 3 | Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | March 2002 | October 2002 |
| NCT00004327 | Completed | Phase 2 | Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia | January 1995 | |
| NCT01408732 | Completed | Phase 1/Phase 2 | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | February 2011 | September 2014 |
| NCT01485224 | Completed | Phase 2 | Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia | November 2011 | October 11, 2016 |
| NCT01752049 | Completed | Phase 1/Phase 2 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | May 2013 | August 30, 2019 |
| NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
| NCT05752253 | Completed | N/A | Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era. | May 5, 2020 | May 30, 2022 |
| NCT02287558 | Completed | Phase 1 | Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study | January 27, 2015 | June 1, 2019 |
| NCT02389959 | Completed | Phase 4 | Intranasal Bevacizumab for HHT-Related Epistaxis | August 4, 2014 | January 23, 2020 |
| NCT02436213 | Completed | N/A | Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs | April 2011 | March 2015 |
| NCT02977637 | Completed | Phase 1 | MRA With Feraheme in HHT | November 2016 | November 2018 |
| NCT03572556 | Completed | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) | June 28, 2018 | May 3, 2020 | |
| NCT03691142 | Completed | Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT) | October 2, 2018 | October 2, 2019 | |
| NCT03695874 | Completed | Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease. | January 28, 2019 | December 28, 2020 | |
| NCT04113187 | Completed | Phase 3 | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | June 23, 2020 | May 19, 2022 |
| NCT04139018 | Completed | Phase 2 | Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia | October 20, 2019 | May 20, 2020 |
| NCT00004649 | Completed | Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients | May 1995 | ||
| NCT00004654 | Completed | Phase 3 | Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia | January 1996 | |
| NCT00375622 | Completed | Phase 2 | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial | February 2005 | June 2006 |
| NCT06261333 | Enrolling by invitation | Quality of Life in Patients With Hemorrhagic Telangiectasia | January 22, 2024 | December 31, 2025 | |
| NCT03850730 | Not yet recruiting | Phase 1/Phase 2 | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | July 1, 2023 | December 31, 2025 |
| NCT01158807 | Recruiting | Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia | April 8, 2010 | June 2025 | |
| NCT05269849 | Recruiting | Phase 2 | Sirolimus for Nosebleeds in HHT | March 16, 2022 | February 10, 2025 |
| NCT05641142 | Recruiting | N/A | Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia | April 7, 2023 | January 2027 |
| NCT05954481 | Recruiting | N/A | Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement | August 3, 2023 | August 2024 |
| NCT06259292 | Recruiting | Comprehensive HHT Outcomes Registry of the United States (CHORUS) | November 13, 2023 | November 2033 | |
| NCT03850964 | Recruiting | Phase 2/Phase 3 | Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) | May 8, 2023 | March 31, 2026 |
| NCT04404881 | Recruiting | Phase 2 | Bevacizumab In Hereditary Hemorrhagic Telangiectasia | November 23, 2020 | February 1, 2027 |
| NCT04469517 | Recruiting | Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia | August 10, 2020 | October 1, 2024 | |
| NCT02106520 | Terminated | Phase 2/Phase 3 | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | April 2014 | September 2015 |
| NCT03549949 | Unknown status | Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany | June 1, 2018 | July 2022 | |
| NCT02458703 | Unknown status | N/A | Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction | May 2015 | May 2018 |
| NCT02963129 | Unknown status | Phase 3 | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT | June 2017 | December 2017 |
| NCT02874326 | Unknown status | Phase 2 | Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber | October 2016 | October 2018 |
- Disase is a (Disease Ontology)
- DOID:178
- Cross Reference ID (Disease Ontology)
- GARD:6626
- Cross Reference ID (Disease Ontology)
- ICD10CM:I78.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:448.0
- Cross Reference ID (Disease Ontology)
- MESH:D013683
- Cross Reference ID (Disease Ontology)
- MIM:187300
- Cross Reference ID (Disease Ontology)
- MIM:600376
- Cross Reference ID (Disease Ontology)
- MIM:601101
- Cross Reference ID (Disease Ontology)
- MIM:615506
- Cross Reference ID (Disease Ontology)
- NCI:C35064
- Cross Reference ID (Disease Ontology)
- ORDO:774
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:266324004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0039445
- Exact Synonym (Disease Ontology)
- Osler hemorrhagic telangiectasia syndrome
- Exact Synonym (Disease Ontology)
- Osler-Weber-Rendu disease
- Exact Synonym (Disease Ontology)
- Rendu-Osler-Weber disease
- OrphaNumber from OrphaNet (Orphanet)
- 774